Supatat ChumnumwatZen Huat LuChonlaphat SukasemMichael David WintherFrancis R. CapuleAsma A.tiyah Abdul HamidBibek BhandariUsa ChaikledkaewNoppadol ChanhomSoranun ChantarangsuAngkana CharoenyingwattanaTong Thi HangTin Maung HlaingKyaw Soe HtunJiraphun JittikoonLy LeSurakameth MahasirimongkolDzul Azri Mohamed NoorJesus ShresthaLakkana SuwannoiPramote TragulpiankitSaowalak TurongkaraveeSukanya WattanapokayakitPhonepadith XangsayarathRika YuliwulandariShamsul Mohd ZainWasun ChantratitaYARSI UniversityInternational University,Vietnam National University Ho Chi Minh CityUNIVERSITI BRUNEI DARUSSALAMKathmandu Medical CollegeUniversity of the Philippines ManilaA-Star, Genome Institute of SingaporeUniversity of MalayaChulalongkorn UniversityNational University of SingaporeFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityThailand Ministry of Public HealthMahidol UniversityUniversiti Sains MalaysiaVingroup Big Data InstituteDefence Services Medical Research Centre (DSMRC)National Center for Laboratory and EpidemiologyMinistry of Health2020-01-272020-01-272019-12-01Public Health Genomics. Vol.22, No.3-4 (2019), 132-13916628063166242462-s2.0-85073694205https://repository.li.mahidol.ac.th/handle/20.500.14594/51294© 2019 S. Karger AG, Basel. Copyright: All rights reserved. Pharmacogenomics (PGx) is increasingly being recognized as a potential tool for improving the efficacy and safety of drug therapy. Therefore, several efforts have been undertaken globally to facilitate the implementation process of PGx into routine clinical practice. Part of these efforts include the formation of PGx working groups working on PGx research, synthesis, and dissemination of PGx data and creation of PGx implementation strategies. In Asia, the Southeast Asian Pharmacogenomics Research Network (SEAPharm) is established to enable and strengthen PGx research among the various PGx communities within but not limited to countries in SEA; with the ultimate goal to support PGx implementation in the region. From the perspective of SEAPharm member countries, there are several key elements essential for PGx implementation at the national level. They include pharmacovigilance database, PGx research, health economics research, dedicated laboratory to support PGx testing for both research and clinical use, structured PGx education, and supportive national health policy. The status of these essential elements is presented here to provide a broad picture of the readiness for PGx implementation among the SEAPharm member countries, and to strengthen the PGx research network and practice in this region.Mahidol UniversityMedicineArticleSCOPUS10.1159/000502916